ARVO 2026 marked a defining moment for the Company as it showcased for the first time its fully integrated vision care and med-tech ecosystem. Through a combined booth space and a scientific program spanning vision care, including myopia management, advanced imaging, AI-powered diagnostics, and therapeutic technologies, EssilorLuxottica demonstrated a highly connected and comprehensive approach to eye care.

Held in Denver, the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) brought together researchers, clinicians, and innovators from around the world to advance eye and vision science.

At this year’s congress, EssilorLuxottica united its capabilities in vision care and medical technologies, including Heidelberg Engineering, RetinAI, and Espansione Group, within a single space. This integrated presence reflected the Company’s connected approach to eye care, bringing together expertise across the full patient journey. New clinical evidence, next-generation technologies, and a strong scientific narrative were showcased through more than 20 peer-reviewed scientific abstracts and over 200 posters and papers citing its technologies.

Advancing myopia management through science

EssilorLuxottica is helping advance a new standard of care in myopia management, as myopia is increasingly recognized as a progressive condition requiring early and sustained intervention.

This evolution reflects a broader shift in eye care, from vision correction to prevention and long-term management throughout the patient journey. At ARVO, the Company highlighted 12 myopia-focused abstracts, including eight from EssilorLuxottica and four from independent research teams, reinforcing the integrated evidence base supporting Essilor Stellest lenses as a leading solution in myopia management across clinical trials, real-world practice and diverse patient populations. In parallel, the research presented further explored the mechanisms involved in myopia progression, advancing the development of more personalized and clinically meaningful solutions.

From advanced imaging and AI analytics to therapy: a collaborative path

One of the defining themes at ARVO this year was the growing role of AI in ophthalmology, with EssilorLuxottica’s Medical Technologies organization positioned at the forefront of this evolution. Heidelberg Engineering, RetinAI and the Espansione Group showcased an integrated med-tech ecosystem for the first time, highlighting how advanced imaging, AI-driven diagnostics, surgical solutions and therapeutic technologies are converging to advance holistic, data-driven patient care. Through new clinical evidence and next-generation innovations, the collaboration demonstrated the potential to enable earlier detection, more personalized treatment pathways, and improved patient outcomes.

EssilorLuxottica’s presence at ARVO 2026 underscored its commitment to advancing a new era of proactive, connected eye care, expanding what the eye can reveal to help people see, live and connect in new ways.